Lastly, Ede et al.’s study explored the safety and immunogenicity of HER-vaxx, a cancer vaccine targeting HER-2, in patients with HER-2-positive G/GEJ cancer, by comparing it with chemotherapy. The gene discussed is ERBB2; the disease is cancer.